Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Gilead Sciences, Inc.
EIR
•Gilead Sciences, Inc.•August 18, 2020

Gilead Sciences, Inc. – FDA EIR, Aug 18, 2020

Record Details

An FDA inspection of Gilead Sciences, Inc. in Foster City, CA, was conducted from August 6-18, 2020, as a hybrid onsite and remote review due to the COVID-19 pandemic. This high-priority Bioresearch Monitoring (BIMO) inspection, conducted under FDA Compliance Program 7348.810 and Good Clinical Practice (GCP) principles, focused on New Drug Application (NDA) 214787 for the investigational drug Remdesivir, specifically Protocols GS-US-540-5773 and GS-US-540-5774. While no FDA Form 483 (Inspectional Observations) was issued during this specific inspection, several "Discussion Items" were raised with management. Key observations included a discrepancy between contractual agreements (Transfer of Regulatory Obligation Agreements vs. Work Orders) regarding responsibility for medical monitoring at international clinical sites. Additionally, documentation for investigator and research staff training at a reviewed clinical site (Dr. Mullane's) for both protocols was found inadequate, showing inconsistencies in attendance records and a lack of proper source documentation for training sessions and protocol amendments. Another point of discussion involved the remote review process for informed consent forms (ICFs), where Clinical Research Associates (CRAs) relied on site staff reading out documentation details instead of direct visual verification due to patient privacy concerns. These discussions highlight areas for potential procedural enhancement in clinical trial oversight and documentation practices under the Food, Drug, and Cosmetic Act (FD&C Act).

Company
Gilead Sciences, Inc.
Inspection date
August 18, 2020
Product type
drugs
Office
San Francisco District Office
People
  • Daniel O’Day (company_representative)
  • Mary Ann Battles (recipient)
  • Ashley Rhoades (company_representative)
  • James Michael Sobczyk (company_representative)
  • Kathleen Mullane (investigator)
View Company Profile

ID · ac7782b1-69ff-4699-ab93-7ddafa77096d

Violation Codes6
21 CFR 1121 CFR 312.53(c)(1)21 CFR 314.50(d)(5)21 CFR 50.25(c)21 CFR 31221 CFR 312.23(a)(1)(viii)

Full citation text and observation details available on the Dashboard.

Other documents for Gilead Sciences, Inc.
  • 483 - 2024-01-22January 22, 2024
  • 483 - 2020-07-22July 22, 2020
  • EIR - 2019-04-04April 4, 2019
  • 483 - 2018-07-17July 17, 2018
  • EIR - 2014-07-25July 25, 2014

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Gilead Sciences, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.